This Week in JAMA | GenomeWeb

This Week in JAMA


In JAMA this week, researchers in the US and Europe say they've developed a genomic predictor of response and survival for taxane-anthracycline chemotherapy in invasive breast cancer. In a multicenter study conducted from June 2000 to March 2010, the researchers measured distant relapse-free survival and absolute risk reduction in patients with newly diagnosed ERBB2–negative breast cancer treated with chemotherapy containing sequential taxane and anthracycline–based regimens.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.